Related by context. All words. (Click for frequent words.) 83 Patent Lawsuit Against 83 Patent Infringement Lawsuit 80 Patent Lawsuit 79 Files Patent Infringement 79 Patent Infringement Suit Against 79 Patent Suit Against 79 Patent Dispute 79 Patent Infringement Case 78 Patent Infringement Suit 78 Wins Patent Infringement 77 Announces Favorable 76 Settles Patent 76 Receives Favorable Ruling 76 Settle Patent 76 Settle Patent Litigation 76 Patent Infringement Litigation 76 Patent Infringement 76 Preliminary Injunction Against 76 Settle Patent Dispute 76 Settle Litigation 75 Announces Dismissal 75 Patent Suit 75 Patent Ruling 75 Antitrust Lawsuit 75 Settles Patent Litigation 75 Files Patent 74 Wins Summary Judgment 74 Infringement Suit 74 Announces Favorable Ruling 74 Q4 Profit Plunges 74 Shareholder Lawsuit 74 Receives Favorable 74 Antitrust Suit 73 Announce License Agreement 73 Gets Favorable 73 Action Suit Against 73 Announce Settlement 73 Infringement Case 73 Antitrust Lawsuit Against 73 Completes Tender Offer 73 Patent Infringement Action 72 Acacia Subsidiary 72 Injunction Against 72 Q1 Loss Widens 72 Receives Patent 72 Lowers Guidance 72 Receives Subpoena 72 Purported Class 72 Infringed 72 Posts Wider Loss 72 Nasdaq Delisting 72 Q3 Loss Narrows 72 Settles Litigation 72 Q2 Adj 71 Q3 Loss Widens 71 Q4 Loss Narrows 71 Infringes 71 Commercializes 71 Plans Job Cuts 71 Stock Soars 71 Posts 4Q Profit 71 Favorable Ruling 71 Boosts Buyback 71 Completes Patient Enrollment 71 Q1 Loss Narrows 71 Patent Issued 71 Issued Patent 71 Q2 Loss Narrows 71 Q4 Loss Widens 71 Reaches Settlement Agreement 71 Q2 Loss Widens 71 4Q Profit Soars 71 Guides Inline 71 Q2 Profit Surges 71 Provides Update Regarding 71 Patent Infringement Lawsuits 70 Files Motion 70 Q1 Adj 70 Board Authorizes 70 Settles Charges 70 Explore Strategic Alternatives 70 Plans Buyback 70 Posts 1Q Profit 70 Claim Against 70 Boosts Guidance 70 CFO Resigns 70 Files Patent Infringement Lawsuit 70 Receives Approvable Letter 70 Q4 Profit Surges 70 Q2 Profit Plunges 70 Q1 Profit Surges 70 Sign Licensing Agreement 70 Receives Notification 70 Pomerantz Law Firm 70 Lawsuit Alleging 70 Licenses Patents 70 Narrows Guidance 70 Q4 Profit Soars 70 3Q Loss Widens 70 Narrows 1Q 70 Jury Verdict 70 4Q Profit Surges 70 Jumps Higher 70 Ups Guidance 70 Q2 Profit Soars 70 Awarded Patent 70 Posts Wider 4Q Loss 70 Announces Immediate Availability 70 Announces Licensing Agreement 70 4Q Loss Widens 70 Delays Filing 70 Gets Favorable Ruling 70 Announces Proposed Settlement 70 Unsolicited Proposal From 70 Settles Patent Dispute 70 Files Countersuit Against 70 Sign License Agreement 70 Posts 2Q 70 Narrows 4Q Loss 70 Shareholder Suit 70 Arthritis Drug 70 Announces FDA Clearance 69 Restates Earnings 69 Provides Status 69 Posts Smaller 69 Q1 Profit Soars 69 Patent Suits 69 Discontinues 69 Countersuit 69 Dismiss Lawsuit 69 Patent Reexamination 69 Wins Dismissal 69 Vigorously Defend 69 Antitrust Case 69 Posts 4Q Loss 69 Q3 Adj 69 Posts 1Q 69 Q3 Profit Surges 69 Suit Vs 69 Updates Guidance 69 Files Patent Infringement Suit 69 Announce Licensing Agreement 69 Begins Shipment 69 Investigation Relating 69 Acquire Assets 69 Boosts Dividend 69 Introduces Next Generation 69 Patent Infringement Claim 69 Settles Patent Infringement Lawsuit 69 Reports Wider Loss 69 Files Amended 69 Trims Loss 69 Meets Estimates 69 Antitrust Settlement 69 Nasdaq Delisting Notice 69 Q3 Profit Soars 69 Backs FY# Outlook 69 Posts 3Q Profit 69 Restate Financials 69 Legal Dispute 69 Lowers Outlook 69 Stock Plunges 69 Provides Guidance 69 Narrows Loss 69 Reaffirms Outlook 69 Extends Tender Offer 69 Increases Share Repurchase 69 Submits NDA 69 Authorizes Additional 69 Shares Plummet 69 Posts 2Q Loss 69 Posts 4Q 69 Reaches Tentative Settlement 69 Shareholder Lawsuit Against 69 Profit Dips 69 Q1 Profit Drops 68 Announces Tentative Approval 68 Completes Enrollment 68 Q2 Profit Plummets 68 Develop Next Generation 68 Announces Stockholder Approval 68 Reach Settlement Agreement 68 Files Lawsuit 68 Posts 2Q Profit 68 Files Patent Application 68 4Q Profit Down 68 Boosts Outlook 68 Settle Lawsuit 68 Successfully Completes Tender Offer 68 False Advertising 68 Unveils Next Generation 68 Licensing Pact 68 Q2 Profit Drops 68 Signs License Agreement 68 Regains Compliance With 68 Settle Shareholder 68 Pending Acquisition 68 Gets Subpoena 68 4Q Profit Jumps 68 Submits Application 68 Generic Version 68 Reaffirms Guidance 68 Shares Soar 68 2Q Profit Surges 68 1Q Loss Widens 68 Settles Suit 68 3Q Profit Rises 68 Announce Collaboration Agreement 68 Antitrust Complaint 68 FDA Accepts 68 Posts Wider 68 FDA Clears 68 4Q Profit Falls 68 Announces Early Termination 68 1Q Profit Falls 68 Q1 Profit Declines 68 Mylan Receives Approval 68 Receives Tentative Approval 68 Licenses Novel 68 Shareholder Suits 68 Posts Narrower Loss 68 Buy Privately Held 68 Files Shelf Registration Statement 68 1Q Loss Narrows 68 Patent Spat 68 3Q Loss 68 2Q Loss Widens 68 Receives NASDAQ 68 KB Home Swings 68 Denies Motion 68 HSR Waiting Period 68 Regains Compliance 68 Immunomedics Announces 68 Raises Guidance 68 Posts Quarterly 68 Exploring Strategic Alternatives 68 Revises FY# Outlook 68 Announce Early Termination 68 Beats Raises Guidance 68 Q4 Profit Declines 68 Q2 Profit Declines 68 Signs Licensing Agreement 68 OKs Buyback 68 3Q Profit Plunges 68 Reaffirms FY# Outlook 68 VP Exercises Options 68 Court Invalidates 68 Settles Dispute 68 Debuts Next Generation 68 Stock Buyback 68 Pending Litigation 68 Q1 Profit Plunges 68 Complaint Against 68 Million Lawsuit Against 68 Antitrust Suit Against 68 Restate Results 68 Fraud Suit Against 67 Analyst Upgrade 67 Amend Merger Agreement 67 Files Voluntary 67 Trademark Infringement Lawsuit 67 Reach Settlement 67 Posts 3Q 67 Files IND 67 Q3 Profit Drops 67 Spins Off 67 4Q Loss 67 Profit Exceeds Estimates 67 Earnings Scorecard 67 Wider Loss 67 1Q Profit Slips 67 Taro Receives 67 Permanent Injunction Against 67 Q4 Profit Drops 67 Files Lawsuits 67 Q1 Profit Jumps 67 Extends Expiration Date 67 Reports Significantly Improved 67 Lifts FY# Outlook 67 2Q Loss Narrows 67 Patent Infringement Claims 67 Receives Notice Regarding 67 Judge Tosses Out 67 PROFILE CO 67 Derivative Lawsuit 67 Delivers Comprehensive 67 Inks Licensing Deal 67 Restates Results 67 Q3 Profit Jumps 67 Introduces Enhanced 67 Universal Shelf Registration 67 Milberg Weiss Announces 67 Posts Strong 67 2Q Profit Up 67 Above Estimates 67 Announces Discontinuation 67 Q4 Adj 67 1Q Profit Declines 67 Confirms Receipt 67 Losses Narrow 67 2Q Profit 67 Non Infringement 67 Announces Effective Date 67 Receives Orphan Drug Designation 67 Wider Than Expected 67 Lowers 3Q 67 1Q Profit Down 67 Board Unanimously Rejects 67 Q3 Profit Plunges 67 Unveils Latest 67 Lowers Price 67 Accounting Errors 67 Antitrust Probe 67 3Q Profit Falls 67 Provides Preliminary 67 Announce Expiration 67 Achieves Milestone 67 Files Suit 67 4Q Profit Drops 67 Tops Forecasts 67 Restructures Operations 67 3Q Profit Jumps 67 Stockholders Approve Acquisition 67 Earnings Postmortem 67 Trademark Dispute 67 Settles Fraud 67 Begins Tender Offer 67 Patent Upheld 67 Lawsuit Dismissed 67 Lawsuit Involving 67 2Q Profit Soars 67 Regains Full 67 Receives Milestone Payment 67 Gets FDA Clearance 67 Q2 Profit Rises 67 Patent Disputes 67 1st Quarter Results 67 Acacia Subsidiary Enters 67 COO Exercises Options 67 Clears Path 67 4Q Profit Slips 67 Announces Definitive Agreement 67 Shareholder Investigation 67 Analyst Downgrade 67 Reports 4Q Loss 67 Hikes Dividend 67 ADDING MULTIMEDIA 67 Regains NASDAQ 67 Collaborates With 67 Consummates 67 Share Repurchases 67 TriCo Bancshares Announces 67 Q3 Profit Declines 67 Net Loss Widens 67 Develop Novel 67 4Q Profit Doubles 66 Settles Patent Suit 66 Delivers Next Generation 66 Completes Purchase Of 66 Announces Organizational Changes 66 Q4 Profit Climbs 66 Files Annual Report 66 Confirms Filing 66 Raises Dividend 66 Terminates Merger Agreement 66 Backs FY# View 66 Sign Definitive Agreement 66 Stockholders Reject 66 Enters Into Settlement Agreement 66 Creditor Protection 66 Restate Financial 66 Settles Patent Lawsuit 66 Resolves Litigation 66 Jointly Announce 66 Boosts Quarterly Dividend 66 Announces License Agreement 66 Introduces Breakthrough 66 Shareholders Approve Merger Agreement 66 3Q Profit Up 66 Settles Lawsuit 66 Reports Narrower 66 Spins Out 66 Outlines Strategy 66 Terminate Merger Agreement 66 Delays Filing Annual Report 66 Reduces Workforce 66 Raises Quarterly Dividend 66 CEO Exercises Options 66 Annual Meeting Date 66 Receives CE Marking 66 Net Loss Narrows 66 Obtains Exclusive License 66 Forecast Quick Facts 66 Commenced Against 66 Canaccord Genuity Reiterates Buy 66 Investigates Proposed Acquisition 66 Shareholder Derivative 66 Submits Supplemental 66 Milestone Payment 66 Announces Enhancements 66 Raises Outlook 66 Expands Scope 66 1Q Profit Doubles 66 Welcomes Analyst Initiation 66 Earnings Cheat Sheet 66 Action Suit 66 Reduces Debt 66 Announces Stock Repurchase 66 Subsidiary Enters 66 Stock Plummets 66 Successfully Completes Acquisition 66 Slashes Guidance 66 Revises Fourth Quarter 66 3Q Profit Drops 66 Takeover Speculation 66 2Q Profit Slides 66 Patent Validity 66 Bearish Speculation 66 Beats Expectations 66 Calls Purchased 66 Aftermarket Movers 66 Shareholders Approve Acquisition 66 Evaluate Strategic Alternatives 66 Directors Authorizes 66 Other OTC MNDP 66 Lawsuit Settled 66 Seeks Approval 66 Expand Relationship 66 Proposed Buyout 66 Stays Neutral 66 Shares Climb 66 Licensing Deal 66 1Q Profit Jumps 66 Profit Soars 66 Q4 Profit Jumps 66 Withdraws Application 66 Sinks Lower 66 1Q Profit Rises 66 Shareholder Claims 66 Explores Strategic Alternatives 66 Has Filed 66 Unveils Newest 66 4Q Profit Up 66 Shares Surge 66 Restructures Debt 66 2Q Profit Down 66 Finalizes Acquisition 66 Judge Nixes 66 Nearly Triples 66 Settle Suits 66 Backdating Case 66 Receives Positive 66 Unveils Revolutionary 66 Stock Tumbles 66 Lawsuit Against 66 Buyout Rumors 66 Receives Confirmation 66 Review Strategic Alternatives 66 Million Verdict 66 Expands Portfolio 66 Receives Clearance 66 Profit Slips 66 Complies With 66 Unveils Expanded 66 Q3 Profit Rises 66 Reaffirms FY# Guidance 66 Ups Bid 66 Lowers Q4 66 Settle Lawsuits 66 4Q Profit Rises 66 Director Exercises Options 66 Misses Expectations 66 Seeks Injunction 66 Receives Unsolicited 66 Strengthens Position 66 Posts Profit 66 Guides Above 66 Mutually Agree 66 Achieves Significant 66 1Q Profit Up 66 Patents Upheld 66 2Q Profit Jumps 66 AUDIO PROVIDED BY 66 Receives Commitment 66 Suit Against 66 Patient Enrollment 66 Provides Shareholder 66 Announces Intent 66 CybeRelease Decliners 66 Streamlines Operations 66 Suspends Dividend 66 Receives FDA Clearance 66 Announce Merger Agreement 66 Announces Effectiveness 66 Terminate Agreement 66 1Q Loss 66 Suits Against 66 Generic Versions 66 Initiates Clinical Trial 66 Awarded Patents 66 Neutral Analyst Blog 66 Initiates Enrollment 66 Taglich Brothers Initiates Coverage 66 Q4 Profit Rises 66 FDA Okays 66 Introduces Innovative 66 Q1 Profit Slips 66 Proxy Fight 66 Completes Sale Of 66 Updates Status 65 Beats Views 65 Withdraws Proposal 65 Files Definitive Proxy 65 Settle Dispute 65 Buyback Plan 65 Initiates Phase II 65 Cross Licensing Agreement 65 Extends Leadership 65 Dramatically Increases 65 Misses Views 65 Revenues Decline 65 Enters Into Licensing Agreement 65 Losses Widen 65 Exceeds Estimates 65 Reconfirms 65 Expand Collaboration 65 Announces Successful Completion 65 Purchases Moore Microprocessor 65 Complete Merger 65 Settles Lawsuits 65 Loss Shrinks 65 Announces Share Repurchase 65 Revises Third Quarter 65 Q1 Profit Decreases 65 Amends Agreement 65 Delivers Enhanced 65 Completes Merger With 65 Obtains Approval 65 Announces Termination 65 SVP Exercises Options 65 Amends Credit 65 Successfully Defends 65 Post Earnings Checkup 65 Submits Biologics License Application 65 Unveil Next Generation 65 NewsBite Downgrade Puts Pressure 65 2Q Profit Falls 65 Traders Hedging Bets 65 3Q Profit Dips 65 Reaches Settlement 65 Completes Divestiture 65 CFO Exercises Options 65 Slashes Price 65 Files Trademark 65 Judge Tosses 65 Movers Roundup 65 SWOT Analysis Aarkstore Enterprise 65 Finalizes Sale 65 Sees Wider 65 Patent Covering 65 Q3 Profit Slips 65 Misses Estimate 65 2nd Quarter Results 65 Issues Statement Regarding 65 Fraud Suit 65 Earns Milestone Payment 65 Action Filed Against 65 Lawsuit Filed 65 Planned Acquisition 65 Q2 Profit Decreases 65 Extends Collaboration 65 For Undisclosed Terms 65 Lifts Dividend 65 Declares Regular Cash Dividend 65 LLP Investigates 65 Host Webcast 65 4Q Profit Slides 65 Faces Delisting 65 Sell Itself 65 3Q Profit Down 65 Q4 Profit Decreases 65 Settle Lawsuit Over 65 Receives Notice From 65 Suit Alleges 65 Expands Relationship With 65 Shelf Registration 65 Seeks Buyer 65 Introduces Powerful 65 Wins Approval 65 NASDAQ Listing Requirements 65 Issues Guidance 65 Trademark Lawsuit 65 Files Suit Against 65 Initiates Clinical Trials 65 Seeks Dismissal Of 65 Unsolicited Tender Offer 65 Strengthens Balance Sheet 65 Announces Share Buyback 65 Puts Purchased 65 Delivers Strong 65 Trademark Suit 65 Canaccord Genuity Maintains Hold 65 Whistleblower Suit 65 Assigned Patent 65 Piracy Lawsuits 65 Countersues 65 Releases Enhanced 65 Enters Oversold Territory 65 StockPreacher.com Issues Trading 65 Provides Updates 65 Releases Next Generation 65 Below Estimates 65 STERIS Corporation Announces 65 Buyout Bid 65 Malpractice Suit 65 Announces Filing 65 3Q Profit 65 Inc. OTCBB MNDP 65 Lawsuit Alleges 65 Ups Ante 65 Settles Lawsuit Against 65 Has Spiked 65 Extends Capabilities 65 Acquire Controlling Interest 65 Reports Positive 65 Stockholders Approve Merger 65 TiVo Posts Narrower 65 Bullish Speculation 65 Delay Filing 65 Files Lawsuit Against 65 Reverses Loss 65 Osteoporosis Drug 65 Cuts Costs 65 Kickback Case 65 Settle Suit 65 Whistleblower Lawsuit 65 Introduces Revolutionary 65 Competition G.1 65 Share Buybacks 65 Announces Intention 65 Announces Initiation 65 Unveils Powerful 65 Q1 Profit Dips 65 Finalizes Purchase Of 65 Secures Patent 65 Remains Neutral 65 Ruling Upheld 65 Technicals Showing Bullish 65 Reminds Shareholders 65 1Q Profit Drops 65 1Q Profit Soars 65 Moving Average Crossover Alert 65 Expands Capabilities 65 Acquire Privately Held 65 Q3 Profit Decreases 65 Execs Plead Guilty 65 1Q Profit Slides 65 Judge Throws Out 65 Posts Loss 65 Settlement Reached 65 Sees 2Q 65 Revises Fiscal 65 Buyout Offer 65 Delivers Breakthrough 65 Obtains Exclusive Rights 65 Files Provisional 65 Bearish Pressure Building 65 Refocuses 65 Suit Settled 65 Eliminates Need 65 Lawsuit Filed Against 65 Begins Shipping 65 Below Consensus 65 Blood Thinner 65 Commences Tender Offer 64 Registration Statement Declared Effective 64 Sweetens Bid 64 Announces Divestiture 64 Receives Delisting Notice 64 #cv# [003] 64 Files Registration Statement 64 Toshiba Develops 64 Inks Pact 64 Announce Licensing 64 License Pact 64 Tops Estimate 64 Provides Updated 64 Beat Estimates 64 Court Dismisses 64 Demonstrates Commitment 64 Biotech Firm 64 2Q Profit Rises 64 Withdraws Offer 64 Fiscal Second Quarter 64 Posts 3Q Loss 64 Citi Downgrades 64 Suit Challenging 64 Approaching Resistance 64 Attracting Bullish Investors 64 #.#B Vioxx 64 Presents Positive 64 Starts Shipping 64 Announces Expiration 64 4Q Profit 64 Raises Bid 64 Epilepsy Drug 64 Stock Downgraded 64 Supplemental Biologics License Application 64 Restate Earnings 64 Completes Restatement 64 Twersky LLP Announces 64 Patent Litigation 64 Significantly Increases 64 Announce Definitive Agreement 64 Lawsuit Challenging 64 Secures Financing 64 Completes Reorganization 64 Extend Partnership 64 Lowers Forecast 64 Announce Filing 64 Unsolicited Proposal 64 Narrower Loss 64 Trademark Infringement 64 Reveals Positive 64 Fiscal Quarter Results 64 3Q Loss Narrows 64 Bullish Average Crossover 64 Declares Increase 64 Misled Investors 64 Announces Preliminary 64 Increases Quarterly Cash Dividend 64 Ships #th 64 1Q Profit Tumbles 64 Court Reverses 64 Increases Stock Buyback 64 Cuts FY# 64 Announce Availability 64 Files Shelf Registration 64 Unveils Innovative 64 3Q Earnings 64 Suit Filed 64 Formalizes 64 Confirms Validity 64 Initiates Patent Infringement 64 Lung Cancer Drug 64 Launches Next Generation 64 Initiates Dosing 64 Settle Dispute Over 64 Signs Merger Agreement 64 Schizophrenia Drug 64 Announces Restatement 64 Raises Buyback 64 Q1 Profit Rises 64 Sharpens Focus 64 Posts Third Quarter 64 Protects Customers 64 Sees 4Q 64 Cholesterol Drug 64 Announce Receipt 64 Options Trader Alert 64 Reports Sharply Higher 64 Declaratory Judgment 64 Gets Approval 64 Subsidiary Files 64 Guides Q2 64 Revises FY# Guidance 64 Resolves Dispute 64 Unwraps 64 Receives Certification 64 Announces Commencement 64 Earnings Surge 64 Restate Prior 64 Announces Definitive Agreements 64 Approves Share Repurchase 64 Announces Repurchase 64 Enhances User Experience 64 Slashes Outlook 64 Completes Previously Announced 64 Zacks Analyst Interview 64 Submits IND 64 4Q Loss Narrows 64 EVP Exercises Options 64 Hostile Bid 64 Suit Claims 64 Zacks Earnings Preview 64 Bullish Technical Alert 64 1Q Profit 64 Releases Statement Regarding 64 Q4 Profit Slips 64 IG HCR ;) CO 64 CRWESelect.com Stock 64 Action Lawsuit 64 Delivers Solid 64 2Q Earnings 64 Seeks Damages 64 Sells Shares 64 Inc. Endures Analyst 64 Commences Mailing 64 Welcomes Analyst 64 Lawsuit Brought 64 Successfully Closes 64 NASDAQ Delisting 64 Above Consensus 64 Boosts Qtr 64 Reduces Size 64 Terminates Agreement 64 Beats Estimates 64 Share Buyback Program 64 Enters Agreement 64 Completes Acquisitions 64 Judge Overturns 64 Profit Misses Estimates 64 Reports Receipt 64 Fistel LLC Announces 64 Updates Outlooks 64 Suit Alleging 64 Announce Collaboration 64 Discrimination Suit Against 64 Posts Lower 64 Court Overturns 64 Enters Joint Venture 64 Profit Slides 64 Guides Below 64 reaffirms FY# outlook 64 Finalize Agreement 64 Appeals Court Upholds 64 Teva Provides Update 64 Activity Alert 64 Defamation Lawsuit 64 Nears Settlement 64 Buyout Talks 64 Generic Version Of 64 Options Activity 64 Bearish MACD 64 3rd Quarter Results 64 Files Bankruptcy 64 Declares Quarterly Dividends 64 1Q Profit Climbs 64 Shares Tumble 64 Files Petition 64 Settle Antitrust 64 Achieves Positive 64 Seek Shareholder Approval 64 Files Antitrust Suit 64 Patent Infringements 64 Sees 3Q 64 Maintains Buy Rating 64 4Q Earnings 64 Profit Doubles 64 FDA Panel Recommends 64 Webcast Presentations 64 Announce Initiation 64 Loss Narrows 64 Misses Forecast 64 Flagship Product 64 Increases Guidance 64 Increases Buyback 64 DVD Copying 64 Receive Milestone Payment 64 Buyout Deal 64 Surpasses Estimates 64 Settle Fraud 64 BioSante Pharmaceuticals Announces 64 IND Filing 64 Receives Approvals 64 Enters Into License Agreement 64 Dramatically Expands 64 Quarterly Earnings Release 63 Webcast Annual Meeting 63 Can Proceed 63 Declares Regular Quarterly Dividend 63 Quarterly Loss Widens 63 Liquidates 63 Aquires 63 Files Preliminary Proxy 63 Completes Transaction 63 Generic Protonix 63 Profit Sinks 63 Refile 63 Profit Beats Estimates 63 #M Buyback [002] 63 Announces Receipt 63 Vioxx Suits 63 SmarTrend Option Scanner 63 Revises Guidance 63 Found Liable 63 Unveils Groundbreaking 63 Lowers FY# Outlook 63 Stock Buyback Plan 63 Receives Orphan Drug 63 Receives Complete Response 63 Releases Upgraded 63 Attorneys Fees 63 Fourth Quarter Earnings Preview 63 Achieves Record Sales 63 Flavored Cigarettes 63 Lawsuit Filed Over 63 Upside Looming 63 Shuffles Execs 63 Anounces 63 Loss Widens 63 Acquires Exclusive 63 Lawsuit Dismissed Against 63 Lawsuits Filed 63 Confirms Guidance 63 Declares Preferred 63 Nanophase Announces 63 Showcases Innovative 63 Announces Redemption 63 Presents Preclinical Data 63 Completes Transition 63 Tops Estimates 63 Files Formal 63 Shareholder Sues 63 Reacquires 63 #cv# [001] 63 Announces Shareholder Approval 63 Considers Sale 63 Drug Candidate 63 Partial Settlement 63 Approves Quarterly Dividend 63 Announces Expanded 63 Subsidiary Receives 63 Hold Fourth Quarter 63 Extends Maturity 63 Exec Pleads Guilty 63 Announce Successful Completion 63 Conference Call TRANSCRIPT 63 Accelerate Commercialization 63 Announces Revised 63 Estimate Analyst Blog 63 Extend Relationship 63 Daytradersdigest.com 63 Lifts FY# Guidance 63 Offers Glimpse 63 Reschedules Fourth Quarter 63 Technicals Showing Bearish 63 Completes Redemption 63 Enrolls First 63 Nasdaq Listing Requirements 63 Profit Triples 63 Shareholder Lawsuits 63 Reaches Settlement With 63 Signs Purchase Agreement 63 Alert Technicals Showing Bearish 63 Exec Bonuses 63 Distribution Pact 63 Put Volume Surges 63 Posts Higher 63 Successfully Concludes 63 CEO Discusses Q1 63 FDA Approvals 63 PPD Declares 63 Releases Second Quarter 63 Broadens Its 63 Drug Coated Stent 63 Earnings Rise Sharply 63 Milestone Payments 63 Settles Suit Over 63 Patent Invalid 63 #.#.# Meldung [001] 63 Endures Analyst Downgrade 63 Enters Into Exclusive 63 Confirms Commitment 63 Share Buyback 63 Judge Clears Way 63 Alert Technicals Showing Bullish 63 Commences Consent Solicitation 63 Lags Estimates 63 Reaches Definitive Agreement 63 Previously Disclosed 63 Obtains License 63 Action Lawsuits 63 Releases Third Quarter 63 Submits Revised 63 Verdict Upheld 63 #M Stock Buyback 63 Regains Nasdaq 63 Bullish Engulfing Pattern 63 Shareholders Approve 63 Beats Analyst 63 Discrimination Case 63 Launches Enhanced 63 Awarded Contract Extension 63 Largest Shareholder 63 Newest Version 63 Misses Estimates 63 Voluntarily Withdraw 63 Renews Agreement 63 #/#/# PriceWatch Alert Technicals [002] 63 Record Third Quarter 63 Patented Technology 63 Stockholders Approve 63 Finalizes Purchase 63 Rehear 63 Announces Underwriters Exercise 63 No. #-# Fed. 63 Underwritten Public 63 Spears Conservatorship